A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizu
A phase 1/2 trial of Doxorubicin, Paclitaxel / nab-paclitaxel, Bevacizumab in sarcomas and ovarian cancer, run by GI Innovation, Inc., now recruiting.
Overview
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) is a phase 1/2 interventional study registered as NCT05824975 by GI Innovation, Inc., with 358 participants planned, started 2023-05-30 and due to reach its primary completion in 2025-11-12. Interventions recorded: GI-102 subcutaneous (SC), GI-102, doxorubicin, paclitaxel, bevacizumab. Conditions listed: Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-
Shares Trastuzumab deruxtecan, Bevacizumab, Ovarian cancer.
- TrialA Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Shares Bevacizumab, Paclitaxel / nab-paclitaxel, Ovarian cancer, Pembrolizumab.
- TrialA Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
Shares Doxorubicin, Bevacizumab, Ovarian cancer, Pembrolizumab.
- TrialA Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Shares Bevacizumab, Hepatocellular carcinoma, Pembrolizumab.
- TrialA Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer
Shares Bevacizumab, Paclitaxel / nab-paclitaxel, Ovarian cancer.
- TrialOregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
Shares Bevacizumab, Paclitaxel / nab-paclitaxel, Ovarian cancer.
- TrialPhase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Shares Bevacizumab, Paclitaxel / nab-paclitaxel, Ovarian cancer.
- TrialKEYNOTE-B96 / ENGOT-ov65
Shares Bevacizumab, Paclitaxel / nab-paclitaxel, Ovarian cancer, Pembrolizumab.